673 - Efficacy of nemolizumab in different subgroups of patients with prurigo nodularis in two randomized, placebo-controlled phase 3 trials

医学 安慰剂 内科学 人口 随机对照试验 不利影响 胃肠病学 病理 环境卫生 替代医学
作者
Shawn G. Kwatra,Martin Metz,Andrew Pink,Gil Yosipovitch,Rola Gharib,Hema Sundaram,Xiaoxiao Chen,Aliene Noda,Zarif K. Jabbar Lopez,Christophe Piketty,Sonja Ständer
出处
期刊:British Journal of Dermatology [Oxford University Press]
卷期号:191 (Supplement_2)
标识
DOI:10.1093/bjd/ljae266.047
摘要

Abstract Introduction It is unknown whether baseline demographics and disease characteristics have an influence on efficacy and safety of nemolizumab in adults with moderate-to-severe prurigo nodularis (PN). Objectives To report safety and efficacy of nemolizumab in the phase 3 studies (OLYMPIA-1 [NCT04501666]1 and OLYMPIA-2 [NCT04501679]2) for different subgroups. Materials & Methods Data were pooled from the pivotal studies in which adults with moderate-to-severe PN were randomized (2:1) to receive nemolizumab (initial 60mg subcutaneous dose, followed by 30mg/60mg [depending on a baseline weight: <90kg/≥90kg] every 4 weeks) or matching placebo. Results Comparisons in all subgroups (age, sex, race, weight, disease severity, atopy, prior treatment) identified efficacy of nemolizumab versus placebo consistent with the overall intention-to-treat population. At Week (W) 16, a ≥4-point improvement in weekly average Peak Pruritus Numerical Rating Scale of nemolizumab vs. placebo was found in 18- to 65-year-old/>65-year-old: 58.6%/54.0% vs 20.0%/14.3%; males/females: 54.7%/59.2% vs 21.1%/17.1%; White/Black/Asian/Other race: 60.3%/56.5%/36.4%/40.0% vs 20.8%/11.8%/12.5%/0%, <90kg/≥90kg baseline weight: 55.6%/60.8% vs 17.9%/20.8%, baseline Investigator’s Global Assessment [IGA] score of 3 [moderate]/4 [severe]: 54.9%/60.8% vs 23.6%/11.7%, with/without history of atopy: 53.8%/59.0% vs 20.3%/17.9% and with/without prior systemic treatment for PN: 57.9%/56.8% vs 14.4%/22.7%. An IGA success (score of 0/1 [clear/almost clear skin] with ≥2-point reduction from baseline) was found in 18- to 65-year-old/>65-year-old: 34.8%/24.0% vs 11.0%/2.4%; males/females: 28.0%/34.5% vs 10.5%/8.1%; White/Black/Asian/Other race: 32.2%/26.1%/33.3%/30.0% vs 8.1%/11.8%/18.8%/0%, <90kg/≥90kg baseline weight: 34.3%/27.2% vs 9.0%/9.4%, baseline IGA score of 3 [moderate]/4 [severe]: 34.0%/29.1% vs 12.7%/3.9%, with/without history of atopy: 29.9%/32.8% vs 4.7%/11.4% and with/without prior systemic treatment for PN: 37.2%/26.8% vs 8.9%/9.3%. Similar results were noted for sleep disturbance. No major difference was reported in the safety profile of nemolizumab between the subgroups. Conclusion Safety and efficacy of nemolizumab monotherapy in itch, skin lesions and sleep disturbance were consistent between the subgroups.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
111111完成签到,获得积分10
刚刚
昏睡的蟠桃应助abcdefj采纳,获得50
1秒前
研路漫漫完成签到,获得积分10
1秒前
胡文静完成签到,获得积分10
1秒前
1秒前
陈陈发布了新的文献求助10
1秒前
林子青完成签到,获得积分10
2秒前
2秒前
小广完成签到,获得积分10
3秒前
3秒前
whale完成签到,获得积分10
3秒前
3秒前
追寻依风应助小飞侠来咯采纳,获得10
3秒前
TianFuAI完成签到,获得积分10
4秒前
WSGQT发布了新的文献求助10
4秒前
wyw完成签到,获得积分10
4秒前
4秒前
汤圆发布了新的文献求助10
4秒前
sueeu完成签到,获得积分20
4秒前
SYLH应助飞快的寒香采纳,获得10
4秒前
5秒前
Hsia完成签到,获得积分10
6秒前
田様应助nano采纳,获得10
6秒前
6秒前
aoao嘉完成签到,获得积分10
6秒前
隐形曼青应助MY采纳,获得10
7秒前
小太阳完成签到,获得积分10
7秒前
醉玉颓山完成签到,获得积分10
7秒前
luo完成签到,获得积分10
7秒前
8秒前
8秒前
勤恳觅珍发布了新的文献求助10
8秒前
背后海亦完成签到,获得积分10
9秒前
三火完成签到,获得积分10
9秒前
9秒前
健壮惋清完成签到 ,获得积分10
10秒前
anyilin完成签到,获得积分10
10秒前
FiroZhang完成签到,获得积分0
10秒前
落雪123发布了新的文献求助10
10秒前
Donby发布了新的文献求助10
10秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Social Research Methods (4th Edition) by Maggie Walter (2019) 2390
A new approach to the extrapolation of accelerated life test data 1000
北师大毕业论文 基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 390
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Robot-supported joining of reinforcement textiles with one-sided sewing heads 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4009254
求助须知:如何正确求助?哪些是违规求助? 3549107
关于积分的说明 11300780
捐赠科研通 3283530
什么是DOI,文献DOI怎么找? 1810370
邀请新用户注册赠送积分活动 886168
科研通“疑难数据库(出版商)”最低求助积分说明 811267